Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints
A.V. Miagkov, … , R.S. Munford, S.S. Makarov
A.V. Miagkov, … , R.S. Munford, S.S. Makarov
Published May 1, 2002
Citation Information: J Clin Invest. 2002;109(9):1223-1229. https://doi.org/10.1172/JCI14536.
View: Text | PDF
Article Genetics

Endogenous regulation of a therapeutic transgene restores homeostasis in arthritic joints

  • Text
  • PDF
Abstract

The treatment of chronic inflammatory diseases is complicated by their unpredictable, relapsing clinical course. Here, we describe a new strategy in which an inflammation-regulated therapeutic transgene is introduced into the joints to prevent recurrence of arthritis. To this end, we designed a recombinant adenoviral vector containing a two-component, inflammation-inducible promoter controlling the expression of human IL-10 (hIL-10) cDNA. When tested in vitro, this system had a low-level basal activity and was activated four to five orders of magnitude by various inflammatory stimuli, including TNF-α, IL-1β, IL-6, and LPS. When introduced in joints of rats with recurrent streptococcal cell wall–induced arthritis, the IL-10 transgene was induced in parallel with disease recurrence and effectively prevented the influx of inflammatory cells and the associated swelling of the joints. Levels of inflammation-inducible hIL-10 protein within the joints correlated closely with the severity of recurrence. An endogenously regulated therapeutic transgene can thus establish negative feedback and restore homeostasis in vivo while minimizing host exposure to the recombinant drug.

Authors

A.V. Miagkov, A.W. Varley, R.S. Munford, S.S. Makarov

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
The two-component C3-tat/HIV promoter is a broadly responsive sensor of ...
The two-component C3-tat/HIV promoter is a broadly responsive sensor of chronic inflammation. (a and b) Induction by the principal proinflammatory cytokines in vitro. Primary synovial fibroblasts were infected in vitro by incubating overnight with the indicated Ad vectors at a multiplicity of infection of 100. Twenty-four hours later, cells were starved in 0.5% FBS medium for 24–48 hours, followed by stimulation for 6 hours with the indicated cytokines (20 ng/ml) or LPS (10 μg/ml). Luciferase activity in cell lysates was normalized to total protein. (a) The levels of inflammation-inducible C3-tat/HIV–driven expression are comparable to those attainable with the CMV promoter. Data are presented as mean of duplicate measurements within an individual experiment; error bars show SD. (b) The C3-tat/HIV promoter provides a large dynamic range of response. The values of fold induction were calculated as the average of readings in independent experiments performed in duplicate (two experiments with IL-1 and IL-6 and three experiments with TNF-α and LPS). (c) In vivo induction following reactivation of SCW arthritis. On day –42, animals were primed by IA injection of PG-APS in both ankle joints. The same joints were injected with the indicated Ad vectors (107 PFU in 10 μl) on day –2. On day 0, arthritis was reactivated by an intravenous injection of PG-APS. Luciferase activity was measured in extracts of pulverized joints (each bar shows the mean ± SD of two joints). In three independent experiments, luciferase activity peaked on day 2–4 and remained elevated through day 4. Unstim., unstimulated; IV, intravenous; rlu, relative luciferase units.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts